SCHEMBL2279523

SCHEMBL2279523

COCCNC(=O)c1ccc(/C=C/C(=O)c2c(O)c3ccccc3[nH]c2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PADI4 Q9UM07 6/20 0.53
ASAH1 Q13510 1/20 0.51
KDM4E B2RXH2 6/20 0.50
USP2 O75604 1/20 0.50
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 2/20 0.49
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
NLRP3 Q96P20 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279527 1.00 PADI4 (0.53) PADI4ASAH1KDM4EUSP2MEN1
SCHEMBL2277535 0.90 MEN1 (0.49) PADI4ASAH1KDM4EUSP2MEN1
SCHEMBL2277539 0.90 MEN1 (0.49) PADI4ASAH1KDM4EUSP2MEN1
SCHEMBL2283784 0.89 PADI4 (0.53) PADI4ASAH1KDM4EUSP2MEN1
SCHEMBL2283781 0.89 PADI4 (0.53) PADI4ASAH1KDM4EUSP2MEN1
SCHEMBL12374855 0.81 MEN1 (0.48) PADI4KDM4EUSP2MEN1KMT2A
SCHEMBL2283850 0.80 PADI4 (0.54) PADI4ASAH1KDM4EMEN1KMT2A
SCHEMBL2283844 0.80 PADI4 (0.54) PADI4ASAH1KDM4EMEN1KMT2A
SCHEMBL2274875 0.79 LMNA (0.50) KDM4EMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2274871 0.79 LMNA (0.50) KDM4EMEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 PADI4 3678/4885ASAH1 174/4885KDM4E 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.